Patents Assigned to Merck Sharp & Dohme
-
Patent number: 12209145Abstract: Disclosed are compounds of Formula I, or a salt thereof: where A, B, D, X, R1, R2 and R8 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.Type: GrantFiled: June 30, 2022Date of Patent: January 28, 2025Assignee: MERCK SHARP & DOHME LLCInventors: Harold B. Wood, Hubert B. Josien, Thomas Joseph Tucker, Angela Dawn Kerekes, Ling Tong, Abbas M. Walji, Anilkumar G. Nair, Fa-Xiang Ding, Elisabetta Bianchi, Danila Branca, Chengwei Wu, Yusheng Xiong, Sookhee Nicole Ha, Jian Liu, Sobhana Babu Boga
-
Patent number: 12208135Abstract: The present invention relates to formulations of dengue virus vaccine comprising at least one live, attenuated dengue virus or live, attenuated chimeric flavivirus, a buffer, a sugar, a cellulose derivative, a glycol or sugar alcohol, optionally an alkali or alkaline salt and an amino acid; and formulations of dengue virus vaccine comprising at least one live, attenuated dengue virus or live, attenuated chimeric flavivirus, a buffer, a sugar of at least 150 mg/ml, a carrier, and optionally an alkali or alkaline salt and an amino acid.Type: GrantFiled: December 6, 2023Date of Patent: January 28, 2025Assignee: Merck Sharp & Dohme LLCInventors: Michael S. Ryan, Sherrie-Ann P. Martin, Morrisa Jones, Justin Stanbro, Akhilesh Bhambhani, Jeffrey Thomas Blue, Heidi Joanne Pixley, Erin J. Green-Trexler, Lynne Ann Isopi
-
Publication number: 20250026762Abstract: The present invention relates to Compounds of Formula (I) and pharmaceutically acceptable salts or prodrug thereof. The present invention also relates to compositions comprising at least one compound of Formula (I), and methods of using the compounds of Formula (I) for treatment or prophylaxis of lysosomal storage diseases, neurodegenerative disease, cystic disease, cancer, or a diseases or disorders associated with elevated levels of glucosylceramide (GlcCer), glucosylsphingosine (GlcSph) and/or other glucosylceramide-based glycosphingolipids (GSLs).Type: ApplicationFiled: November 28, 2022Publication date: January 23, 2025Applicant: Merck Sharp & Dohme LLCInventors: Mark E. Fraley, Tao Liang, H. Marie Loughran, Anthony J. Roecker, Kathy M. Schirripa, Ling Tong, Ashwin U. Rao
-
Publication number: 20250026759Abstract: The present disclosure is directed to tetrahydroquinazoline derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV naïve cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).Type: ApplicationFiled: July 5, 2024Publication date: January 23, 2025Applicant: Merck Sharp & Dohme LLCInventors: Michael J. Breslin, Antonella Converso, Abdellatif El Marrouni, Ashley Forster, David N. Hunter, Anthony W. Shaw, William D. Shipe, Yunlong Zhang
-
Publication number: 20250019376Abstract: The present invention relates to monobactam compounds of Formula I: The present invention also relates to pharmaceutical compositions comprising a monobactam compound of structural formula I or a pharmaceutically acceptable salt thereof. The invention further relates to the compounds of formula (I) for use in methods for treating a bacterial infection, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic. The present invention discloses the synthesis and characterisation of exemplary compounds as well as biological assays thereof. An exemplary compound is e.g.Type: ApplicationFiled: November 16, 2022Publication date: January 16, 2025Applicant: Merck Sharp & Dohme LLCInventors: Helen Y. Chen, Shuzhi Dong, Zhiyong Hu, Jing Su, Tao Yu, Yong Zhang
-
Patent number: 12195445Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.Type: GrantFiled: May 24, 2022Date of Patent: January 14, 2025Assignee: Merck Sharp & Dohme LLCInventors: Ashok Arasappan, Ian M. Bell, Michael J. Breslin, Christopher James Bungard, Christopher S. Burgey, Harry R. Chobanian, Jason M. Cox, Anthony T. Ginnetti, Deodial Guy Guiadeen, Kristen L. G. Jones, Mark E. Layton, Hong Liu, Jian Liu, James J. Perkins, Shawn J. Stachel, Linda M. Suen-Lai, Zhe Wu
-
Publication number: 20250011453Abstract: Provided herein are methods of treating cancer (e.g., ovarian, mesothelioma, triple-negative breast cancer), which comprise administering to a human patient in need thereof: (a) a PD-1 antagonist; (b) an ILT4 antagonist; and (c) one or more chemotherapeutic agents. Also provided are pharmaceutical compositions and kits containing such agents for the treatment of cancer.Type: ApplicationFiled: July 18, 2022Publication date: January 9, 2025Applicant: Merck Sharp & Dohme LLCInventor: Rachel A. Altura
-
Publication number: 20250009751Abstract: The present disclosure is directed to pharmaceutical formulations comprising an amorphous inhibitor of hepatitis C virus NS5A. These pharmaceutical formulations may be prepared by roller-compaction or wet-granulation methods. The present disclosure is also directed to oral dosage forms, such as tablets, comprising such pharmaceutical formulations.Type: ApplicationFiled: September 23, 2024Publication date: January 9, 2025Applicant: Merck Sharp & Dohme LLCInventors: Sutthilug Sotthivirat, Joyce Stellabott, Walter R. Wasylaschuk
-
Publication number: 20250011732Abstract: The present invention relates to a scalable process for the purification of human cytomegalovirus particles from cell culture medium. In particular, the process involves a two step chromatography process starting with an anion exchange chromatography step followed by a polishing chromatography step selected from mixed mode chromatography or cation exchange chromatography.Type: ApplicationFiled: July 11, 2024Publication date: January 9, 2025Applicant: Merck Sharp & Dohme LLCInventors: Adam Kristopeit, Janelle Konietzko, Wanli MA, Katherine Phillips, Andrew Swartz, Sheng-Ching Wang, Marc D. Wenger, Matthew Woodling, Tiago Matos
-
Publication number: 20250002448Abstract: The present disclosure relates to compounds of formula (I) that are useful as modulators of a7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease. Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.Type: ApplicationFiled: September 19, 2022Publication date: January 2, 2025Applicant: MERCK SHARP & DOHME LLCInventors: Ian M. Bell, Brendan M. Crowley, James Fells, Patrick Bazzini, Jean-Marie Contreras, Fabrice Garrido, Belinda C. Huff, Christophe Joseph, Christophe Morice, Dharam Paul, Aurelie Witzel
-
Publication number: 20250000994Abstract: The present disclosure relates to methods of treating a cellular proliferative disorder (e.g., cancer) comprising administering: (a) an anti-human PD-1 antibody or antigen binding fragment thereof; and (b) an Immunoconjugate of Formula (I): wherein: Ab is an antibody that binds to Trop-2; and n is an integer from 1 to 10. Also disclosed are therapeutic combinations and kits containing such agents for the treatment of cancers.Type: ApplicationFiled: December 7, 2023Publication date: January 2, 2025Applicants: Merck Sharp & Dohme LLC, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Inventors: Junyou Ge, Xiaoping Jin, Yina Diao, Yalan Yang, Yujie Fu, Dian Jing, Hongbo Zhong, Omobolaji Akala, Elliot Keith Chartash, Maria Catherine Pietanza, Bin Zhao
-
Publication number: 20250000744Abstract: An ampoule includes a body having a cavity for storing a medicament, a neck coupled to the body and defining a nozzle in communication with the cavity of the body, a removable cap coupled to the nozzle, and an anti-choking miter coupled to the removable cap, the anti-chocking miter being wider than the removable cap.Type: ApplicationFiled: November 11, 2022Publication date: January 2, 2025Applicant: Merck Sharp & Dohme LLCInventors: Ramprasad B. Halthore, Atul Karande, Derrick M. Smith
-
Publication number: 20250000990Abstract: The present disclosure relates to methods of treating a cellular proliferative disorder (e.g., cancer) comprising administering: (a) an anti-human PD-1 antibody or antigen binding fragment thereof; and (b) an Immunoconjugate of Formula (I): wherein: Ab is an antibody that binds to Trop-2; and n is an integer from 1 to 10. Also disclosed are therapeutic combinations and kits containing such agents for the treatment of cancers.Type: ApplicationFiled: December 7, 2023Publication date: January 2, 2025Applicants: Merck Sharp & Dohme LLC, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Inventors: Junyou Ge, Xiaoping Jin, Yina Diao, Jiacheng Yang, Yujie Fu, Zhijiao Qiao, Lihua Chen, Omobolaji Akala, Elliot Keith Chartash, Sarper Toker, Christian H. Poehlein, Blanca Homet Moreno
-
Patent number: 12178842Abstract: Disclosed are compounds of Formula A, or a pharmaceutically acceptable salt thereof: where A, X, R1, and R2 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.Type: GrantFiled: October 31, 2022Date of Patent: December 31, 2024Assignee: MERCK SHARP & DOHME LLCInventors: Hubert Josien, Abbas Walji, Harold B. Wood, Fa-Xiang Ding, Jian Liu, Thomas Joseph Tucker, Michael Man-Chu Lo, Liangqin Guo
-
Patent number: 12180219Abstract: The application is directed to efficient and economical processes as described in more detail below for the preparation of the beta 3 agonists of the formula of I-7 and intermediate compounds that can be used for making these agonists. The present disclosure relates to a process for making beta-3 agonists and intermediates using ketoreductase (KRED) biocatalyst enzymes and methods of using the biocatalysts.Type: GrantFiled: April 29, 2024Date of Patent: December 31, 2024Assignee: MERCK SHARP & DOHME LLCInventors: Feng Xu, Zhuqing Liu, Richard Desmond, Jeonghan Park, Alexei Kalinin, Birgit Kosjek, Hallena Strotman, Hongmei Li, Johannah Moncecchi
-
Patent number: 12180226Abstract: Described herein are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein A, R1, R2, R3, W, X, Y, Z, m, n and p are as defined herein. The compounds of Formula I act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related diseases.Type: GrantFiled: October 25, 2022Date of Patent: December 31, 2024Assignee: Merck Sharp & Dohme LLCInventors: Abdelghani Abe Achab, Zachary G. Brill, Jenny Lorena Rico Duque, Xavier Fradera, Joey L. Methot, Phieng Siliphaivanh, Jing Su, Brandon A. Vara, Erin F. DiMauro
-
Publication number: 20240424109Abstract: An insulin conjugate comprising or consisting of a tetra-valent sugar cluster is described. The tetra-valent sugar cluster is provided by tetra-dentate linker having four arms, wherein each arm of the tetra-dentate linker is independently covalently linked to a ligand comprising or consisting of a saccharide, such as a monosaccharide, disaccharide, trisaccharide, tetrasaccharide, or branched trisaccharide. In particular aspects, the insulin conjugate displays a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose.Type: ApplicationFiled: November 16, 2022Publication date: December 26, 2024Applicant: Merck Sharp & Dohme LLCInventors: Pei Huo, Songnian Lin, Christopher R. Moyes, Dmitri A. Pissarnitski, Zhiqiang Zhao, David N. Hunter, Yuping Zhu
-
Publication number: 20240425596Abstract: The invention provides compositions of anti-PD-1 antibodies or antigen-binding fragments thereof with less than or equal to about 3.0% oxidation of Met105 in the CDRH3 heavy chain region, and methods of obtaining the purified compositions. The invention also provides compositions comprising anti-PD-1 antibody main species and acidic species thereof, wherein the amount of acidic species is about 1.0-12.0%.Type: ApplicationFiled: September 6, 2024Publication date: December 26, 2024Applicant: Merck Sharp & Dohme LLCInventors: Mark A. Brower, Chung-Jr Huang, Brian Wai Kwan, William Nicholas Napoli, Bhumit A. Patel, Nuno J. Dos Santos Pinto, Douglas Dennis Richardson, II, Sen Xu
-
Publication number: 20240424218Abstract: In some examples, a vial-to-syringe converter includes a plunger rod, an adapter including a body having a piercing spike, a receiver and a lumen extending between the spike and the receiver, the body further including at least one laterally-extending flange, and a needle in communication with the receiver and configured to deliver a medicament to a patient's body.Type: ApplicationFiled: November 1, 2022Publication date: December 26, 2024Applicant: Merck Sharp & Dohme LLCInventors: Daniel A. Bonanno, Eduardo Cristofolli, Cassie Megna, Wail A. Rasheed, Ophelia L. Wells
-
Publication number: 20240425524Abstract: Described herein are compounds of Formula I; and pharmaceutically acceptable salts thereof, wherein A, X, R1, R2, m, n, and p are as defined herein. The compounds of Formula I, and pharmaceutically acceptable salts thereof, act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related diseases.Type: ApplicationFiled: October 24, 2022Publication date: December 26, 2024Applicant: Merck Sharp & Dohme LLCInventors: Abdelghani Abe Achab, Jenny Lorena Rico Duque, Xavier Fradera, Joey L. Methot, Phieng Siliphaivanh, Brandon A. Vara, Hongjun Zhang
